Skip to main content
. 2020 Oct 22;8(11):E1664–E1672. doi: 10.1055/a-1236-3350

Table 1. Summary of pooled rates.

Outcome Pooled rate (95 % confidence interval) I2; 95 % prediction interval
Technical success 84.8 % (79.1–89.2); 22 studies 61 %; 56 to 96

  • USA

 77.5 % (61.2–88.3); 4 studies 0 %; 38 to 95

  • Europe

 85.3 % (72–92.9); 5 studies 79 %; 11 to 99

  • Japan

 91.2 % (83–95.6); 9 studies 0 %; 81 to 96

  • Others (multiple countries, Israel, India)

 82 % (67.1–91.1); 4 studies 84 %; 4 to 99

  • Multicenter

 87.5 % (77.7–93.4); 6 studies 66 %; 41 to 98

  • Single-center

 83.5 % (76.1–88.9); 16 studies 58 %; 54 to 95

  • Manuscripts

 84.4 % (77.4–89.5); 17 studies 68 %; 48 to 97

  • Abstracts

 86.5 % (74.3–93.5); 5 studies 0 %; 63 to 96

  •  > 12-month follow-up

 84.1 % (71.8–91.6); 5 studies 64 %; 41 to 94

  •  < 12-month follow-up

 92.6 % (84.4–96.6); 6 studies 30 %; 52 to 94
Successful PD drained 77.5 % (63.1–87.4); 11 studies 88 %; 21 to 98

  • Europe

 69.2 % (47–85); 4 studies 85 %; 2 to 99

  • Others

 89.4 % (75.7–95.8); 4 studies 9 %; 46 to 99

  • USA, Japan

 Insufficient data -NA-

  • Multicenter

 87.2 % (69.5–95.3); 4 studies 80 %; 4 to 95

  • Single-center

 70.2 % (52.1–83.5); 7 studies 87 %; 43 to 93

  •  > 12-month follow-up

 79.5 % (47.7–94.3); 3 studies 68 %; 3 to 98

  •  < 12-month follow-up

 84.2 % (53–96.2); 3 studies 93 %; 2 to 98
Clinical success 89.2 % (82.1–93.7); 18 studies 73 %; 50 to 98

  • Japan

 92.5 % (83.9–96.7); 9 studies 50 %; 44 to 99

  • Europe

 76.2 % (58.9–87.7); 4 studies 76 %; 9 to 99

  • USA

 Insufficient data -NA-

  • Others (multiple countries, Israel, India)

 91 % (80.2–96.2); 4 studies 0 %; 65 to 98

  • Multicenter

 90.2 % (77.9–96); 5 studies 49 %; 47 to 99

  • Single-center

 88.3 % (79–93.8); 13 studies 71 %; 41 to 98

  • Manuscripts

 89.6 % (81.2–94.5); 14 studies 75 %; 45 to 99

  • Abstracts

 88.8 % (67.7–96.8); 4 studies 64 %; 7 to 99

  •  > 12-month follow-up

 86.4 % (71.9–94.1); 5 studies 71 %; 43 to 98

  •  < 12-month follow-up

 85.3 % (70.3–93.5); 6 studies 77 %; 42 to 99
Adverse events (all) 18.1 % (14.2–22.9); 22 studies 45 %; 8 to 36

  • Europe

 18.7 % (12.4–27.2); 5 studies 32 %; 6 to 44

  • Japan

 15.8 % (10.3–23.6); 9 studies 31 %; 5 to 39

  • USA

 12.8 % (7.4–21.3); 4 studies 0 %; 4 to 40

  • Others (multiple countries, Israel, India)

 27.9 % (19.4–38.2); 4 studies 48 %; 6 to 70

  • Multicenter

 24.3 % (16.8–33.7), 6 studies 51 %; 8 to 55

  • Single center

 15.9 % (11.8–21); 16 studies 30 %; 7 to 31

  • Manuscript

 17.9 % (13.4–23.5); 17 studies 50 %; 7 to 39

  • Abstracts

 18.2 % (10.8–29); 5 studies 32 %; 5 to 49
Adverse events by ASGE Lexicon

  • Mild

 13 % (8.3–19.9); 19 studies 69 %; 2 to 49

  • Moderate

 9.9 % (6.5–14.8); 19 studies 48 %; 3 to 30

  • Severe

 3.9 % (2.5–5.9); 19 studies 0 %; 2 to 6
Post EUS-PDD individual adverse events

  • Pancreatitis

 6.6 % (4.5–9.4); 21 studies 5 %; 4 to 11

  • Bleeding

 4.1 % (2.7–6.2); 21 studies 0 %; 3 to 6

  • Perforation and/or pneumoperitoneum

 3.1 % (1.9–5); 21 studies 0 %; 2 to 5

  • Pancreatic leak and/or pancreatic fluid collection

 2.3 % (1.4–4); 21 studies 0 %; 1 to 4

  • Infection

 2.8 % (1.7–4.6); 21 studies 0 %; 2 to 5

  • Nonspecific post-procedure abdominal pain warranting inpatient monitoring

 13.9 % (8.2–22.6); 10 studies 65 %; 3 to 49

  • Stent-related adverse events

 21.3 % (11.5–36.2); 12 studies 85 %; 2 to 80

  • Reintervention

 15.2 % (9.1–24.1); 6 studies 44 %; 4 to 45
Publication bias Eggers P  = 0.01

PD, pancreatic duct; ASGE, American Society for Gastrointestinal Endoscopy; EUS-PDD, endoscopic ultrasound-guided pancreatic duct drainage.